TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline in D. Pteronyssinus HDM-specific IgG4 Antibodies in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in HDM-specific IgE Blocking Factor (IgE-BF) in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with BM cellularity failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with ANC failure without evidence of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate Relief of Abdominal Pain or Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neonatal rooting, latching, sucking, and swallowing behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage SPO2 Accuracy Root-Mean Square (ARMS) at Forehead Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage SPO2 Accuracy Root-Mean Square (ARMS) at Torso Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage SPO2 Accuracy Root-Mean Square (ARMS) at BACK Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HR Accuracy Root-Mean Square (ARMS) at Forehead Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of HR Accuracy Root-Mean Square (ARMS) at TORSO Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in tumour volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Thoracic spine range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Investigator Overall Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gastric Emptying of Solids (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postpartum Hemorrhage Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Children Who Developed Postextubation Adverse Respiratory Events
Endpoint domain: Adverse events/effects
Primary endpoint: Food and Beverage Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Local (Injection Site) Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Unsolicited Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Solicited Systemic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Solicited Local AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Unsolicited Vaccine-Related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Abnormal Laboratory Values Reported as Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: 2-year incidence of brain metastases
Endpoint domain: Mortality/survival
Primary endpoint: Serum inflammatory factor level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum ATP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximum Edi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with at least 1 Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Hyperhidrosis Disease Severity Scale (HDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of necrotic tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of inflammatory tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Efficacy in treating skin mycoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Distribution-of-stiffness index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Heightened-sensitivity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in lean soft tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in squat 1 repetition maximum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in bench press 1 repetition maximum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stroke or death within 30 days after enrollment
Endpoint domain: Mortality/survival
Primary endpoint: any stroke in the territory of the symptomatic intracranial artery beyond 30 days through 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Number and severity of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Child perception questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of catheter related thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in G-tube rate insertions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increased percent of subjects achieving full oral feedings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Earlier NG tube removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cumulative duration of abnormal SSEP changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum tolerated dose (MTD) / Recommended Dose (DR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity profile evaluating the combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of en-masse retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of en-masse retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IVF outcomes fertilization rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Efficacy of AP23573 in endometrial cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area of type IIA fibers in vastus lateralis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postoperative pain scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sample Mean of Differences of Mean Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sample Mean of Std. Dev of Local Power Differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Emotional Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in (Non)Acceptance of Negative Emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Anhedonia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: First-cycle Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: biopsy proven acute rejection event
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of opportunistic infection
Endpoint domain: Adverse events/effects
Primary endpoint: Potency Rates (Ability to Obtain an Erection Sufficient for Penetration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant stability quote (ISQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue questionnaire results
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of adverse events and safety signals
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Plasma Concentration (Cmax) of MORF-057
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Cmax (Tmax) of MORF-057
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in child body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Health-Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in child objective executive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Median Nerve Distal Motor Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrence of Cutaneous Abscess
Endpoint domain: Adverse events/effects
Primary endpoint: recurrent non-variceal upper GI bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area under plasma concentration-time curve from time 0 to dosing interval (tau) (AUC0-τ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration-time curve from time 0 to last measurable plasma concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who completed surveys
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With HIV-1 RNA <50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence of ARDS
Endpoint domain: Adverse events/effects
Primary endpoint: Aortic valve calcium assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Liver Stiffness Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patency Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Intrauterine Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Frequency of Congruence of Nerve Integrity and Vocal Cord Functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain physiologic measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall acceptance of SDF
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: decrease in average pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Change in Hot Flash Activity Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Vault cytology adequacy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nature, frequency and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of metabolic tracers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hyperammonemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: outcome in patients with propionic acidemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall quality of bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Modified FTM Essentials Tremor Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Annual Non-cystic Fibrosis Bronchiectasis Pulmonary Exacerbation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Patients that Experience a Problem during Cancer Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate according to RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Saxagliptin Area Under the Plasma Concentration Versus Time Curve (AUC[0-inf])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saxagliptin Observed Maximum Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metformin Area Under the Plasma Concentration Versus Time Curve (AUC[0-inf])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metformin Observed Maximum Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbers of breast cancers detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Median Progression Free Survival (mPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Survival without molecular relapse
Endpoint domain: Mortality/survival
Primary endpoint: Change in EF score in the IIEF
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Seroconversion rate of the IgG antibody against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geomean titers of the IgG antibody against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate of the neutralizing antibody against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geomean titers of the neutralizing antibody against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety based on adverse event reports
Endpoint domain: Adverse events/effects
Primary endpoint: Safety based on clinical laboratory findings
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Concentration (Cmax) of Cabotegravir (CAB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time (AUC[0-t]) of CAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Phase Half-life (t1/2) of CAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incision Healing Complications
Endpoint domain: Adverse events/effects
Primary endpoint: number of patients with previously undiagnosed GD identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with previously undiagnosed LALD identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of days wearing the device
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fatigue Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Perceived Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Identification of sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Level of Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Endothelial Glycocalyx Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knowledge, attitude and practice of dentists regarding child abuse and neglect
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Positive Anti-drug Antibodies Response
Endpoint domain: Adverse events/effects
Primary endpoint: Complication-free treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ASIA motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: the ability to walk without assistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal Cord Independence Measure (SCIM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steady glucose metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Score of Neurocognitive Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in Neurocognitive Performance at 1 week post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in Neurocognitive Performance at 1 month post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of use of generic immunosuppressive drugs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Facial Wrinkle Severity Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance walked in the 6 Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue index from the isokinetic fatigue test
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Six-minute Walk Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of the full procedure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Baseline Dyspnea Index (BDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Transition Dyspnea Index (TDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Six Minute Walk Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admit again to ICU
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of Ventricular Tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Paced Auditory Serial Addition Task (PASAT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Stroop Color-Word Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: California Verbal Learning Test-II (CVLT-II)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Controlled Oral Word Association Test (COWAT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Annual eGFR decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of completion of FOBT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cumulative time of radiofrequency catheter ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Energy delivery to achieve bidirectional isthmus block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Breast Cancer Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Microbiological load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Columbia - Suicide Severity Rating Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of PF 04802540 and its metabolite, PF 04831035
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Esophageal Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemically verified smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac filling pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac stroke volume (SV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Global Impression (CGI-21)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Standardized Executive Function Test Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Residual pulmonary alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: time until death
Endpoint domain: Mortality/survival
Primary endpoint: Gonadal radiation dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmax of CKD-519
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-last of CKD-519
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ of CKD-519
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRR assess by investigators per the 2014 Lugano classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects with treatment-related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: duration of CR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required for adequate intraperitoneal insufflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Drug Self-administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status